ProcCluster® from portfolio company inflamed pharma granted US patent

Xlife Sciences AG

/ Key word(s): Miscellaneous

ProcCluster® from portfolio company inflamed pharma granted US patent
01.11.2022 / 07:00 CET/CEST

 

Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manufacture of the active ingredient ProcCluster® and for its use in pharmaceutical dosage forms and their production.

Oliver R. Baumann, CEO of Xlife Sciences, commented: “This patent significantly strengthens inflamed pharma’s intellectual property position in the pharmaceutical market. We are pleased to be able to make our active ingredient ProcCluster® available also to patients in the USA in the future.”

The granted US patent 11,440,872 covers on the one hand the production of the active ingredient of ProcCluster® as such, and on the other hand the production of various forms of application, for example capsules and tablets for oral administration, semi-solid preparations such as creams, gels and ointments for dermal application or liquid variants for use as inhalation as well as infusion or injection solutions. The underlying technology of procaine clustering – in which the active ingredient is incorporated into a protective shell – can be extended to other suitable and interesting active ingredient candidates, with currently unfavorable formulation properties. Thus, this principle represents a very good option for modifying the active ingredient properties and opens up a wide field of applications for the respective candidates.

 

The active ingredient ProcCluster® is based on the active substance procaine and is manufactured by inflamed pharma in compliance with GMP. Procaine is used in various indications such as neural therapy for the treatment of chronic pain. inflamed pharma is seeking approval for the oral application of ProcCluster® with an indication in the inflammatory pain area; Germany/Europe is foreseen as the first market.

 

Financial calendar

CIPH Frankfurt                         November 1-3, 2022

Medica Düsseldorf                   November 14, 2022

Annual Report 2022                 April 20, 2023

AGM 2023                                June 22, 2023

Half-Year Report 2023             September 21, 2023

 

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG
 
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
ISIN: CH0461929603
WKN: A2PK6Z
Börsen: SIX Swiss Exchange  

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.


End of Media Release


show this